FDA approves Indocin oral suspension generic for inflammatory conditions

The FDA has approved an abbreviated new drug application from ANI Pharmaceuticals for indomethacin oral suspension, a generic version of Indocin oral suspension, according to a press release from the manufacturer.
In a statement, ANI Pharmaceuticals President and CEO Nikhil Lalwani said the approval comes with a competitive generic therapy designation (CGT) granting the company’s generic version of Indocin (Zyla Life Sciences) oral suspension 180-day exclusivity.
“ANI continues to hold the second-highest number of CGT approvals in the U.S. generics market, highlighting the strong

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart